Announcements Trials
Browse Landscape

Phase

Phase 3 11Phase 2 10Phase 1/2 4Phase 1 4Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphatic Diseases 1Leukemia, B-Cell 1Heart Failure 1

Interventions

Specimen Handling 3Cisplatin 3Magnetic Resonance Spectroscopy 2Letrozole 2Human Papillomavirus Recombinant Vaccine nonavalent 2Diosmin 2Carboplatin 2trametinib 1toripalimab 1tocilizumab 1sofosbuvir-velpatasvir drug combination 1ruxolitinib 1rozanolixizumab 1pyrotinib 1pirtobrutinib 1olutasidenib 1obinutuzumab 1niraparib 1naldemedine 1idelalisib 1human papillomavirus vaccine, L1 type 16, 18 1fluciclovine F-18 1enfortumab vedotin 1darolutamide 1dabrafenib 1cabozantinib 1apalutamide 1adacel 1acalabrutinib 1Watchful Waiting 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × obinutuzumab × 30 days × Clear all
NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

AstraZeneca

Phase 4 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡